StemiRNA Therapeutics Biotech is Biotechnology in China that focus on infectious diseases business. Founded in 2016. They cover business area such as researcher, biotechnology, RNA technology-base drug development, independently-develop mrna drug project, mrna-base personalized cancer vaccine, mrna vaccine, infectious disease, protein, genetic disease, cure, solution, patient.
2016
( 8 years old in 2024 )
Infectious Diseases
-
Room 603-604, Building 2
1295 Chuanqiao Road, Pudong New Area
Shanghai
China
Private
researcherbiotechnologyRNA technology-base drug developmentindependently-develop mrna drug projectmrna-base personalized cancer vaccinemrna vaccineinfectious diseaseproteingenetic diseasecuresolutionpatient
* We use standard office opening hours in near StemiRNA Therapeutics Biotech's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
StemiRNA Therapeutics Biotech is Biotechnology business from China that founded in 2016 (8 years old in 2024), StemiRNA Therapeutics Biotech business is focusing on Infectious Diseases.
StemiRNA Therapeutics Biotech headquarter office and corporate office address is located in Room 603-604, Building 2 1295 Chuanqiao Road, Pudong New Area Shanghai China.
StemiRNA Therapeutics Biotech was founded in China.
In 2024, StemiRNA Therapeutics Biotech is currently focus on infectious diseases sector.
Above is snippet of Google Trends for "infectious diseases" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with StemiRNA Therapeutics Biotech, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
